Phosphorylated targets | Clinical response | Survival | |||||||
---|---|---|---|---|---|---|---|---|---|
CR | PR | SD ≥ 6 months | SD < 6 months | PD | CBR | P value | Median PFS (95% CI), months | P value | |
AKT | Â | Â | Â | Â | Â | Â | 0.367 | Â | 0.597 |
Negative | 0 | 0 | 5 | 2 | 0 | 71.4% | Â | 11.3 (3.858-18.742) | Â |
Positive | 0 | 1 | 4 | 4 | 2 | 45.5% | Â | 5.6 (0.313-10.887) | Â |
mTOR | Â | Â | Â | Â | Â | Â | 0.023 | Â | 0.001 |
Negative | 0 | 0 | 0 | 3 | 1 | 0% | Â | 3.7 (2.003-5.397) | Â |
Positive | 0 | 1 | 9 | 3 | 1 | 71.4% | Â | 11.3 (5.250-17.350) | Â |
S6RP | Â | Â | Â | Â | Â | Â | 0.069 | Â | 0.002 |
Negative | 0 | 0 | 0 | 2 | 1 | 0% | Â | 3.7 (0.499-6.901) | Â |
Positive | 0 | 1 | 9 | 4 | 1 | 66.7% | Â | 11.3 (6.882-15.718) | Â |
4EBP1 | Â | Â | Â | Â | Â | Â | 0.617 | Â | 0.160 |
Negative | 0 | 0 | 1 | 2 | 0 | 40.0% | Â | 3.8 (3.640-3.960) | Â |
Positive | 0 | 1 | 8 | 4 | 2 | 60.0% | Â | 8.6 (0.647-16.553) | Â |